Supporting evidence comes from the Framingham Heart Study in 2019; after multivariate correction for main cardiovascular risk factors, NAFLD patients showed significantly higher serum concentrations of inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), intercellular adhesion molecule 1 (ICAM-1), P-selectin, interleukin 6 (IL-6) and urinary isoprostanes [80]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.